Resunab Fast Tracked to Treat Scleroderma, Plus, Infliximab Biosimilars in Europe

Author: Michele B. Kaufman
Date Published: September-2015
Source: The Rheumatologist

Resunab for Systemic Sclerosis Receives FDA Fast-Track Status Systemic sclerosis (scleroderma) affects mostly women in mid-life and is a rare, serious and chronic autoimmune disorder. There are no treatments approved by the FDA, and the disease confers significant morbidity and mortality.